Changes of cerebrospinal fluid monoamine metabolites during long-term antidepressant treatment

European Neuropsychopharmacology

Volumn 10, Issue 5, 2000, Pages 341-349

  Bäckman, Jakob ^a   Alling, Christer ^a   Alsén, Margot ^a   Regnéll, Göran ^a   Träskman Bendz, Lil ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

5 HIAA; Antidepressants; Cerebrospinal fluid; MHPG

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; DIAZEPAM; DRUG METABOLITE; HALOPERIDOL; IMIPRAMINE; MAPROTILINE; NEUROLEPTIC AGENT; NITRAZEPAM; NORCLOMIPRAMINE; NORDAZEPAM; NORTRIPTYLINE; OXAZEPAM; PERPHENAZINE; THIORIDAZINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE TIME EFFECT RELATION; DRUG CEREBROSPINAL FLUID LEVEL; DRUG METABOLISM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERM EXPOSURE; LUMBAR PUNCTURE; MALE; PRIORITY JOURNAL; SEROTONIN RELEASE; SUICIDE ATTEMPT;

EID: 0343390461     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(00)00089-4     Document Type: Article

References (26)

1. Åberg-Wistedt A., Ross S.B., Jostell K.G., Sjöquist B. A double blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression. II. Biochemical findings. Acta Psychiatr. Scand. 66:1982;66-82.
2. Ågren H., Mefford I.N., Rudorfer M.V., Linnoila M., Potter W.Z. Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF. J. Psychiatr. Res. 20:1986;175-193.
3. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition :1980;APA, Washington, DC.
4. Åsberg M., Bertilsson L., Tuck D., Cronholm B., Sjöqvist F. Indoleamine metabolites in the cerebrospinal fluid of depressed patients before and during treatment with nortriptyline. Clin. Pharmacol. Ther. 14:1973;277-286.
5. Åsberg M., Montgomery S.A., Perris C., Schalling D., Sedvall G. A comprehensive psychopathological rating scale. Acta Psychiatr. Scand. Suppl. 271:1978;5-27.
6. Åsberg M., Eriksson B., Mårtensson B., Träskman-Bendz L., Wägner A. Therapeutic effects of serotonin uptake inhibitors in depression. J. Clin. Psychiatry. 46:(Suppl. 4):1986;23-35.
7. Bertilsson L., Tuck J.R., Siwers B. Biochemical effects of zimelidine in man. Eur. J. Clin. Pharmacol. 18:1980;483-487.
8. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15:1994;220-226.
9. Bowden C.L., Koslow S.H., Hanin I., Maas J.W., Davis J.M., Robins E. Effects of amitriptyline and imipramine on brain amine neurotransmitter metabolites in cerebrospinal fluid. Clin. Pharmacol. Ther. 37:1985;316-324.
10. De Bellis M.D., Geracioti Jr T.D., Altemus M., Kling M.A. Cerebrospinal fluid monoamine metabolites in fluoxetine treated patients with major depression and healthy volunteers. Biol. Psychiatry. 33:1993;636-641.
11. Faull K.F., Pascoe N., Maddaluno J., Greene K.A., Wiener S.G. Passage of MHPG from plasma to CSF in a non-human primate. J. Neurosci. Res. 27:(4):1990;533-540.
12. Hsiao J.K., Ågren H., Bartko J.J., Rudorfer M.V., Linnoila M., Potter W.Z. Monoamine neurotransmitter interactions and the prediction of antidepressant response. Arch. Gen. Psychiatry. 44:1987;1078-1083.
13. Ko H.C., Lu R.B., Shiah I.S., Hwang C.C. Plasma free 3-methoxy-4-hydroxyphenylglycol predicts response to fluoxetine. Biol. Psychiatry. 41:1997;774-781.
14. Lundmark J., Wålinder J., Alling C., Manniche P.M., Dalgaard L. The effect of paroxetine on cerebrospinal fluid concentrations of neurotransmitter metabolites in depressed patients. Eur. Neuropsychopharmacol. 4:1994;1-6.
15. Maas J.W., Koslow S.H., Katz M.M., Bowden C.L., Gibbons R.L., Stokes P.E., Robins E., Davis J.M. Pretreatment neurotransmitter metabolite levels and response to tricyclic antidepressant drugs. Am. J. Psychiatry. 141:1984;1159-1171.
16. Mårtensson B., Nyberg S., Toresson G., Brodin E., Bertilsson L. Fluoxetine treatment of depression: clinical effects, drug concentration and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid. Acta Psychiatr. Scand. 79:1989;586-596.
17. 3H-imipramine binding and serotonin uptake and concentration in major depressive disorder. Acta Psychiatr. Scand. 83:1991;125-133.
18. Montgomery S.A., Åsberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry. 134:1979;382-389.
19. Muscettola G., Goodwin F.K., Potter W.Z., Claeys M.M., Markey S.P. Imipramine and desipramine in plasma and cerebrospinal fluid: Relationship to clinical response and serotonin metabolism. Arch. Gen. Psychiatry. 35:1978;621-625.
20. Nordin C., Bertilsson L., Siwers B. Clinical and biochemical effects during treatment of depression with nortriptyline: the role of 10-hydroxynortriptyline. Clin. Pharmacol. Ther. 42:1987;10-19.
21. Potter W.Z. Adrenoceptors and serotonin receptor function: relevance to antidepressant mechanisms of action. J. Clin. Psychiatry. 56:(Suppl. 4):1996;4-8.
22. Potter W.Z., Scheinin M., Golden R.N., Rudorfer M.V., Cowdry R.W., Calil H.M., Ross R.J., Linnoila M. Selective antidepressants and cerebrospinal fluid: lack of specificity on norepinephrine and serotonin metabolites. Arch. Gen. Psychiatry. 42:1985;1171-1177.
23. Risby E.D., Hsiao J.K., Sunderland T., Ågren H., Rudorfer M.V., Potter W.Z. The effects of antidepressants on the cerebrospinal fluid homovanillic acid/5-hydroxyindoleacetic acid ratio. Clin. Pharmacol. Ther. 42:1987;547-554.
24. Sulser F. Serotonin-norepinephrine receptor interactions in the brain: implications for the pharmacology and pathophysiology of affective disorders. J. Clin. Psychiatry. 48:(Suppl. 3):1987;12-18.
25. Swahn C.G., Sandgärde B., Wiesel F.A., Sedvall G. Simultaneous determination of the three major monoamine metabolites in brain tissue and body fluids by a mass fragmentographic method. Psychopharmacology. 48:1976;147-152.
26. Träskman L., Åsberg M., Bertilsson L., Cronholm B., Mellström B., Neckers L.M., Sjöqvist F., Thorén P., Tybring G. Plasma levels of chlorimipramine and its demethyl metabolite during treatment of depression. Clin. Pharmacol. Ther. 26:1979;600-610.